Buy Ipamorelin UK | HPLC-Verified | COA Per Batch

Ipamorelin Peptide | Buy Ipamorelin UK | Selective GH Secretagogue | Research Use Only

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide and the first selective growth hormone secretagogue (GHS) of its class, studied extensively in laboratory research for its highly specific GH-releasing activity via the GHS-R1a (ghrelin) receptor — available to buy in the UK from Peptides Lab UK in high-purity lyophilised form, >99% HPLC-verified purity, with batch-specific COA and fast UK dispatch for laboratory and in vitro research use only.

Distributed by Peptides Lab UK in a high-purity lyophilised format, for laboratory research use only. This compound is handled in controlled settings for in vitro and pre-clinical studies, with no applications in human or veterinary medicine. Each batch undergoes rigorous quality analysis to ensure >99% purity (HPLC verified).

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed by Novo Nordisk, displaying high GH-releasing potency and efficacy both in vitro and in vivo. It was identified through an extensive medicinal chemistry programme focused on compounds lacking the central Ala-Trp dipeptide of GHRP-1, ultimately yielding a compound with a distinct and highly specific pharmacological profile.

What sets Ipamorelin apart from other peptides in the GHRP class is its exceptional selectivity. While other GHRPs such as GHRP-2 and GHRP-6 stimulate the release of both GH and adrenocorticotropic hormone (ACTH) and cortisol, Ipamorelin acts selectively on GH release alone — making it one of the most precise research tools available for studying the GH axis in isolation.

As a research compound, Ipamorelin UK has one of the most robust published profiles within the GHRP class, with peer-reviewed studies spanning GH secretion, longitudinal bone growth, and body composition research.

How Does Ipamorelin Work?

Ipamorelin functions as a selective agonist of the GHS-R1a receptor — the same receptor activated by the endogenous hormone ghrelin. Unlike GHRH analogues (such as Sermorelin or CJC-1295) which act at the GHRH receptor via cyclic AMP-dependent signalling, Ipamorelin triggers rapid GH release through GHS-R–mediated pathways at the hypothalamus and anterior pituitary.

GHS-R1a Receptor Activation

Pharmacological profiling using GHRP and GHRH antagonists clearly confirmed that Ipamorelin stimulates GH release via a GHRP-like receptor, with in vitro potency and efficacy comparable to GHRP-6 in primary rat pituitary cell assays.

Selective GH Release — No ACTH or Cortisol Effect

Unlike GHRP-6 and GHRP-2, which both resulted in elevated plasma ACTH and cortisol levels in swine models, Ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation alone — even at doses more than 200-fold higher than the ED50 for GH release. This selectivity makes Ipamorelin uniquely valuable for isolating GH-specific signalling without confounding adrenal axis effects.

GH Pulse Kinetics

Pharmacokinetic modelling in healthy male subjects showed that plasma Ipamorelin levels persisted longer than plasma GH levels and continued to drive smaller secondary GH pulses, with peak GH concentration occurring at approximately 0.67 hours post-administration and declining to low levels by 6 hours.

What Does Ipamorelin Do in Research?

In laboratory settings, Ipamorelin has been studied across several biological systems. Research has examined its role in:

• GH secretion stimulation via selective GHS-R1a agonism
• IGF-1 axis modulation and downstream anabolic signalling research
• Longitudinal bone growth and bone mineral content investigations
• Body composition and lean tissue research in pre-clinical models
• Comparative GHRP selectivity and receptor-binding studies
• Postoperative gastrointestinal motility research via ghrelin receptor pathways
• Synergistic GH axis research when combined with GHRH analogues such as CJC-1295

Ipamorelin and Longitudinal Bone Growth Research

In adult female rats administered Ipamorelin subcutaneously three times daily for 15 days, a dose-dependent increase in longitudinal bone growth rate was observed — rising from 42 µm/day in the vehicle group to 52 µm/day at the highest dose — confirming GH-mediated effects on skeletal tissue in pre-clinical models.

Ipamorelin and Bone Mineral Content Research

In 13-week-old female Sprague-Dawley rats treated continuously for 12 weeks, Ipamorelin increased bone mineral content as measured by dual X-ray absorptiometry (DXA), with pQCT analysis showing the increase in cortical BMC was attributable to increased cross-sectional bone area rather than changes in volumetric bone mineral density.

Ipamorelin and GH Secretagogue Selectivity Research

Ipamorelin was identified as the first GHRP-receptor agonist with a selectivity for GH release comparable to that of GHRH itself, making it a highly valuable research tool for studying the GH axis without unwanted hormonal interference.

What Do Studies Say About Ipamorelin?

Ipamorelin has been the subject of peer-reviewed research since its initial characterisation in 1998, with studies spanning neuroendocrinology, bone biology, body composition, and pharmacokinetics.

Ipamorelin vs GHRP-6 and GHRP-2

In conscious swine, Ipamorelin released GH with an ED50 of 2.3 nmol/kg and an Emax of 65 ng GH/ml plasma — closely comparable to GHRP-6 — while GHRP-2 demonstrated higher potency but lower efficacy. Critically, FSH, LH, PRL, and TSH plasma levels were unaffected by any of the GHS compounds tested.

Ipamorelin and IGF-1 Research

Research comparing Ipamorelin to GHRH-receptor agonists confirmed that elevated GH following GHS-R activation stimulates downstream IGF-1 production in hepatic and peripheral tissues, with studies examining differences in secretion kinetics, peak amplitude, and duration of GH and IGF-1 signalling between receptor subtype classes.

Ipamorelin as a Foundation for Drug Discovery

Ipamorelin served as the structural foundation for the development of NN703, an orally active and selective GHS that entered Phase II clinical trials — further validating the pharmacological template that Ipamorelin established within the GHRP class.

Ipamorelin and Postoperative Research

A prospective, randomised, controlled proof-of-concept study investigated Ipamorelin as a ghrelin mimetic for the management of postoperative ileus in bowel resection patients, reflecting the breadth of research interest in GHS-R1a agonism beyond the GH axis.

Key cited studies:

• Raun K et al. (1998) — Ipamorelin, the First Selective Growth Hormone Secretagogue — Eur J Endocrinol. PubMed ID: 9849822
• Johansen PB et al. (1999) — Ipamorelin Induces Longitudinal Bone Growth in Rats — Growth Horm IGF Res. PubMed ID: 10373343
• Svensson J et al. (2000) — Ipamorelin and GHRP-6 Increase Bone Mineral Content in Adult Female Rats — J Endocrinol. PubMed ID: 10828840
• Gobburu JV et al. (1999) — Pharmacokinetic-Pharmacodynamic Modelling of Ipamorelin in Human Volunteers — Pharmaceutical Research, 16(9)
• Rasmussen MH et al. (1998) — Ipamorelin: A New and Very Potent Growth Hormone Secretagogue — Growth Horm IGF Res, 8(4): 332
• Ishida J et al. (2020) — Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development — JCSM Rapid Communications. DOI: 10.1002/rco2.9

Ipamorelin vs Other GH Research Peptides

Feature	Ipamorelin	GHRP-6	GHRP-2	CJC-1295
Receptor Target	GHS-R1a	GHS-R1a	GHS-R1a	GHRH-R
GH Selectivity	High (no ACTH/cortisol)	Low (raises ACTH/cortisol)	Low (raises ACTH/cortisol)	Moderate
Potency vs GHRP-6	Comparable	Reference	Higher	Different class
Half-Life	~2 hours	~15–60 min	~15–60 min	Days (with DAC)
Research Use	GH axis isolation	Broad GHS research	GH/ACTH research	Sustained GH release

Ipamorelin’s unique combination of potent GH release and minimal off-target hormonal effects makes it the preferred research tool when studying the GH axis in isolation, without confounding adrenal or gonadal axis interference.

Quality & Purity Assurance

Every batch of Ipamorelin from Peptides Lab UK is:

• >99% pure — HPLC and mass spectrometry verified
• Supplied with a full Certificate of Analysis (COA) on request
• Lyophilised powder for maximum stability and long shelf life
• Manufactured under strict, controlled laboratory conditions
• Consistent batch-to-batch quality for reproducible research results

Buy Ipamorelin UK — Product Specifications

Property	Detail
Purity	>99% (HPLC verified)
Form	Lyophilised powder
Storage	Store dry at -20°C; protect from light
Solubility	Bacteriostatic water, sterile water, or suitable laboratory solvents

Ipamorelin Research Applications

Ipamorelin peptide UK is supplied strictly for the following in vitro and pre-clinical research uses:

• GHS-R1a receptor binding and selective GH axis pathway studies
• GH and IGF-1 secretion modelling in pre-clinical models
• Longitudinal bone growth and bone mineral content research
• Body composition and lean tissue biology studies
• Comparative GHRP selectivity and off-target hormonal profiling
• Postoperative gastrointestinal motility and ghrelin receptor pathway research
• Structure–activity relationship (SAR) investigations within the GHRP peptide class
• Synergistic GH secretion research in combination with GHRH analogues

Why Buy Ipamorelin from Peptides Lab UK?

Peptides Lab UK is a trusted UK peptides supplier, providing research-grade compounds verified by independent HPLC testing. When you buy Ipamorelin in the UK from us, you receive:

• >99% purity, HPLC and MS verified, third-party tested
• Full COA documentation per batch
• Fast same-day UK dispatch with tracked delivery
• Competitive pricing with bulk research discounts available
• Trusted by researchers across the UK and Europe

Research Disclaimer All products supplied by Peptides Lab UK are intended strictly for in vitro laboratory research and scientific study use only. They are not intended for human consumption, veterinary use, or any medical or therapeutic application. Ipamorelin is not a licensed medicine or drug and has not been approved by the MHRA, FDA, or any regulatory authority for human or veterinary use. All research citations on this page relate to pre-clinical studies and peer-reviewed pharmacological research and do not constitute a claim of safety or therapeutic efficacy. Peptides Lab UK accepts no liability for any misuse of research compounds. By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.